Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3500 - Correlation of circulating tumor cells with myeloid-derived suppressive cells in the peripheral blood of patients with advanced small cell lung cancer


10 Oct 2016


Poster display


Ippokratis Messaritakis


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


I. Messaritakis, A. Koutoulaki, D. Aggouraki, E..K. Vetsika, E. Politaki, S. Apostolaki, V. Georgoulias, A. Kotsakis

Author affiliations

  • Laboratory Of Translational Oncology, School of Medicine, University of Crete, 71110 - Heraklion/GR


Abstract 3500


The accumulation of Myeloid-derived Suppressor Cells (MDSCs) and the Circulating Tumor Cells (CTCs) have been proposed as negative prognostic biomarkers in several tumors, including SCLC. However, no studies have shown a correlation of the MDSCs with CTCs in SCLC patients. We aimed to investigate the clinical relevance of CTCs and MDSCs in progressing patients with advanced SCLC.


Peripheral blood was obtained from 32 SCLC patients at the time of progression after 1st line chemotherapy and 31 healthy controls (HC). Immune cells were determined using flow cytometry and CTCs were detected using both the CellSearch System (CS) and immunofluorescence double staining of PBMCs with anti-TTF1 and/or anti-CD56 and anti-CD45 antibodies (IF). The median percentage of patients MDSCs at baseline was used to characterize MDSCs as high or low. For the CTCs detection using the CS and IF, the cut-off values were ≥5 and ≥1 CTCs, respectively.


The percentage of naïve CD4+ T cells was decreased in patients vs NC at baseline. The whole population of MDSCs (CD33+LinHLA-DR−/low), as well as the granulocytic (G)-(CD15+CD14CD33+CD11b+) and the monocytic (M)-MDSCs (CD14+CD15+CD33+CD11b+LinHLA-DR−/low) were significantly increased in patients (p 


We showed an increased frequency of M-MDSCs in the blood of patients with SCLC at relapse exhibiting a positive correlation with CTCs. These observations seem to indicate that some CTCs' subpopulations may be escape and proliferate in patients with active immunosuppressive mechanisms.

Clinical trial identification


Legal entity responsible for the study



Laboratory of Translational Oncology, School of Medicine, University of Crete


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings